Back to Newsroom

Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of APD371

SAN DIEGO, April 29, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor currently in development for the treatment of pain and potentially fibrotic diseases.

Click here to read more